GE HealthCare raised its profit forecasts for 2023 after recording better-than-expected financials in its Q2 earnings report.

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

New research has uncovered protein signatures associated with different forms of Alzheimer's disease (AD), including markers found in plasma, cerebrospinal fluid (CSF), and brain tissue.

Roche said Tuesday that it secured US Food and Drug Administration 510(k) clearances for a pair of assays to aid diagnosis of Alzheimer's disease measuring levels of beta-amyloid and tau proteins.

Alzheimer's disease (AD) is a common neurodegenerative disease that affects the cognitive and memory abilities of the brain.

C2N Diagnostics announced the publication of a study further confirming the sensitivity of its PrecivityAD blood test for diagnosing Alzheimer’s disease.

Roche said Wednesday that it has entered a collaboration with drug maker Eli Lilly to support development of Roche's Elecsys Amyloid Plasma Panel (EAPP), a blood test for aiding earlier diagnosis of Alzheimer's disease.

Roche announced on Thursday that two of its tests for Alzheimer's disease have received 510(k) clearance from the US Food and Drug Administration.

The US Food and Drug Administration said on Wednesday it has issued de novo classification to Fujirebio Diagnostics' Lumipulse G β-Amyloid Ratio (1-42/1-40) test, allowing the company to market it as a tool for diagnosing Alzheimer's disease.

With the help of single-cell sequencing, a team from Boston Children's Hospital, the Broad Institute, Harvard Medical School, and elsewhere has found evidence for enhanced somatic mutation in brain cells from individuals with Alzheimer's disease.